The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III clinical trial of two different arms of a combined treatment with carnitine plus celecoxib with or without megestrol acetate for patients with cancer-related anorexia/cachexia syndrome (CACS).
C. Madeddu
No relevant relationships to disclose
F. Panzone
No relevant relationships to disclose
R. Serpe
No relevant relationships to disclose
G. Antoni
No relevant relationships to disclose
M. C. Cau
No relevant relationships to disclose
F. M. Tanca
No relevant relationships to disclose
M. Dessi'
No relevant relationships to disclose
M. Mura
No relevant relationships to disclose
Q. Mela
No relevant relationships to disclose
A. Macciò
No relevant relationships to disclose
G. Mantovani
No relevant relationships to disclose